Elixiron Immunotherapeutics Announces Closing of $27 Million Series A-1 Financing Round to Progress Alzheimer's Disease and Vitiligo Clinical-Stage Assets
SAN FRANCISCO, Aug. 23, 2021 -- (Healthcare Sales & Marketing Network) -- Elixiron Immunotherapeutics, Inc., a privately held company developing therapeutics for cancer, neurological diseases and inflammatory disorders, has announced the closing of a Seri... Biopharmaceuticals, Venture Capital Elixiron Immunotherapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Alzheimer's | Brain | Cancer | Cancer & Oncology | Marketing | Neurology | Pharmaceuticals | Venture Capital | Vitiligo